PfHRP2_RDTs | Asymptomatic infections | |||||
---|---|---|---|---|---|---|
Pfldh_qPCR | Microscopy | |||||
Positive | Negative | Total | Positive | Negative | Total | |
Positive | 150 | 24 | 174 | 119 | 55 | 174 |
Negative | 37 | 55 | 92 | 11 | 81 | 92 |
Total | 187 | 79 | 266 | 130 | 136 | 266 |
Se (%) (CI 95%) | 80 (74, 86) | Â | 92 (85, 96) | Â | ||
Sp (%) (CI 95%) | 70 (58, 80) | Â | 60 (51, 68) | Â | ||
PPV (%) (CI 95%) | 86 (81, 90) | Â | 84 (81, 87) | Â | ||
NPV (%) (CI 95%) | 60 (52, 68) | Â | 75 (63, 84) | Â | ||
Kappa* | 0.48, p < 0.001 |  | 0.51, p < 0.001 |  |
PfHRP2_RDTs | Symptomatic infections | |||||
---|---|---|---|---|---|---|
Pfldh_qPCR | Microscopy | |||||
Positive | Negative | Total | Positive | Negative | Total | |
Positive | 128 | 3 | 131 | 114 | 17 | 131 |
Negative | 43 | 22 | 65 | 8 | 57 | 65 |
Total | 171 | 25 | 196 | 122 | 74 | 196 |
Se (%) (CI 95%) | 75 (68, 81) | Â | 93 (88, 97) | Â | ||
Sp (%) (CI 95%) | 88 (69, 98) | Â | 77 (66, 86) | Â | ||
PPV (%) (CI 95%) | 98 (94, 99) | Â | 97 (95, 98) | Â | ||
NPV (%) (CI 95%) | 34 (28, 41) | Â | 64 (47, 78) | Â | ||
Kappa* | 0.37, p < 0.001 |  | 0.72, p < 0.001 |  |